
Renal Cell Carcinoma
Latest News

Latest Videos

CME Content
More News

Mipsagargin, a first-in-class prodrug, showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.

Jordi Bruix, MD, discusses findings of a comparison of modified (m)RECIST and RECIST 1.1 assessments in the RESORCE trial.

In updated results presented at the 2017 International Liver Congress, Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.

Researchers have identified higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion as independent prognostic factors of recurrence in patients treated with sorafenib Nexavar for hepatocellular carcinoma.

Results from a study of microRNA-34a and natural killer cells presented at the 2017 International Liver Congress suggest that microRNA-34a, one of the most documented tumor suppressor microRNAs, could have a role in regulating cytotoxicity and development of the effector NK cells and their target cells.

Hans J. Hammers, MD, PhD, discusses findings from a phase I study of alpha-1, 3 galactosyltransferase-expressing allogeneic RCC immunotherapy.

Patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).

Metastatic RCC, Progressing on Multiple Therapies






Choosing Second-Line Therapy for Metastatic Kidney Cancer









The findings from a phase II study of intermittent sunitinib in patients with previously untreated mRCC demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.

Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.


































